← Leaderboards

Darell D Bigner

Duke University

Google Scholar ↗PubMed ↗ORCID ↗

$25,397,506

Attributed

$25,397,506

Total exposure

16

Grants

11

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $5.4M · FY2005–22

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

Funding mix

By agency

NIH$76,098,817 · 21

By mechanism

P50$34,530,842 · 9

P01$19,748,056 · 4

R37$8,087,593 · 1

P30$6,656,394 · 4

R35$6,075,934 · 1

P20$999,998 · 2

Top collaborators

No co-investigators on record.

Most similar at Duke University

Same institution · by research overlap

Matthias Gromeier$11,871,021
John H Sampson$43,413,436
Michael Clavon Brown$1,028,443
Roger E McLendon$2,833,433
Dorothy A Sipkins$8,543,606

Others in their field

Top investigators on “Brain Neoplasms”

Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
Walter John Curran · Thomas Jefferson University$98,312,615
Gregory H Reaman · National Childhood Cancer Foundation$78,833,655
Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
Robert H Vonderheide · University Of Pennsylvania$60,987,353

Research focus

Brain NeoplasmsClinical TrialsGrantGliomaVaccinesMalignant Neoplasm Of BrainNeuro-OncologyCellsTumorMonoclonal AntibodiesProgramsClinical ResearchDesignMonitorRecurrenceResearch PersonnelGlioblastomaImmunotoxinsCentral Nervous System NeoplasmsNeoplastic CellFundingResponseTemozolomideChemotherapy

Grant awards (118)

Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma$550,752

P01 · FY2022 · CA · contact PI

Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas$919,541

R35 · FY2021 · CA · contact PI

Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma$497,607

P01 · FY2021 · CA · contact PI

Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas$845,062

R35 · FY2020 · CA · contact PI

Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma$493,987

P01 · FY2020 · CA · contact PI

Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas$879,333

R35 · FY2019 · CA · contact PI

Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma$475,986

P01 · FY2019 · CA · contact PI

Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas$912,796

R35 · FY2018 · CA · contact PI

Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma$440,797

P01 · FY2018 · CA · contact PI

Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas$636,627

R35 · FY2017 · CA · contact PI

Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors$2,641,256

P01 · FY2016 · CA · contact PI

Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas$933,896

R35 · FY2016 · CA · contact PI

EGFRwt and EGFRvlll Dual-Specific Immunotoxin for Glioblastoma Multiforme$306,146

P01 · FY2016 · CA · contact PI

Administration$56,083

P01 · FY2016 · CA · contact PI

Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors$3,698,322

P01 · FY2015 · CA · contact PI

Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas$948,679

R35 · FY2015 · CA · contact PI

EGFRwt and EGFRvlll Dual-Specific Immunotoxin for Glioblastoma Multiforme$651,410

P01 · FY2015 · CA · contact PI

Administration$52,175

P01 · FY2015 · CA · contact PI

Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors$3,469,664

P01 · FY2014 · CA · contact PI

EGFRwt and EGFRvlll Dual-Specific Immunotoxin for Glioblastoma Multiforme$638,550

P01 · FY2014 · CA · contact PI

Administration$51,144

P01 · FY2014 · CA · contact PI

Neuro-Oncology$41,819

P30 · FY2014 · CA · contact PI

Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors$3,054,903

P01 · FY2013 · CA · contact PI

SRC on Primary Tumors of the CNS$1,201,868

P50 · FY2013 · NS · contact PI

EGFRwt and EGFRvlll Dual-Specific Immunotoxin for Glioblastoma Multiforme$573,030

P01 · FY2013 · CA · contact PI

IND, REGULATORY AND BIOINFORMATICS$150,976

P50 · FY2013 · NS · contact PI

ADMINISTRATIVE CORE$131,088

P50 · FY2013 · NS · contact PI

Administration$49,859

P01 · FY2013 · CA · contact PI

Neuro-Oncology$26,285

P30 · FY2013 · CA · contact PI

Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors$1,651,535

P01 · FY2012 · CA · contact PI

SRC on Primary Tumors of the CNS$1,252,033

P50 · FY2012 · NS · contact PI

Brain Tumors - Immunological and Biological Studies$681,848

R37 · FY2012 · CA · contact PI

EGFRwt and EGFRvlll Dual-Specific Immunotoxin for Glioblastoma Multiforme$339,032

P01 · FY2012 · CA · contact PI

IND, REGULATORY AND BIOINFORMATICS$157,073

P50 · FY2012 · NS · contact PI

ADMINISTRATIVE CORE$136,299

P50 · FY2012 · NS · contact PI

Administration$55,818

P01 · FY2012 · CA · contact PI

Neuro-Oncology$28,771

P30 · FY2012 · CA · contact PI

Neuro-Oncology$2,501

P30 · FY2012 · CA · contact PI

SRC on Primary Tumors of the CNS$1,255,050

P50 · FY2011 · NS · contact PI

Brain Tumors - Immunological and Biological Studies$682,341

R37 · FY2011 · CA · contact PI

IND, REGULATORY AND BIOINFORMATICS$154,001

P50 · FY2011 · NS · contact PI

ADMINISTRATIVE CORE$134,052

P50 · FY2011 · NS · contact PI

Neuro-Oncology$30,025

P30 · FY2011 · CA · contact PI

SRC on Primary Tumors of the CNS$1,279,737

P50 · FY2010 · NS · contact PI

Brain Tumors - Immunological and Biological Studies$703,967

R37 · FY2010 · CA · contact PI

IND, REGULATORY AND BIOINFORMATICS$165,719

P50 · FY2010 · NS · contact PI

ADMINISTRATIVE CORE$144,751

P50 · FY2010 · NS · contact PI

Neuro-Oncology$32,918

P30 · FY2010 · CA · contact PI

SRC on Primary Tumors of the CNS$1,270,806

P50 · FY2009 · NS · contact PI

Brain Tumors - Immunological and Biological Studies$690,468

R37 · FY2009 · CA · contact PI

IND, REGULATORY AND BIOINFORMATICS$166,751

P50 · FY2009 · NS · contact PI

ADMINISTRATIVE CORE$120,830

P50 · FY2009 · NS · contact PI

NEUROONCOLOGY$35,892

P30 · FY2009 · CA · contact PI

SPORE in Brain Cancer$25,969

P50 · FY2009 · CA · contact PI

SPORE in Brain Cancer$2,346,429

P50 · FY2008 · CA · contact PI

SRC on Primary and Metastatic Tumors of the CNS$1,270,346

P50 · FY2008 · NS · contact PI

Brain Tumors - Immunological and Biological Studies$670,357

R37 · FY2008 · CA · contact PI

CORE--CAREER DEVELOPMENT PROGRAM$79,367

P50 · FY2008 · CA · contact PI

CORE--DEVELOPMENTAL RESEARCH PROGRAM$79,365

P50 · FY2008 · CA · contact PI

NEUROONCOLOGY$25,090

P30 · FY2008 · CA · contact PI

SPORE in Brain Cancer$2,322,240

P50 · FY2007 · CA · contact PI

SRC on Primary and Metastatic Tumors of the CNS$1,308,421

P50 · FY2007 · NS · contact PI

Brain Tumors - Immunological and Biological Studies$642,571

R37 · FY2007 · CA · contact PI

SPORE in Brain Cancer$146,300

P50 · FY2007 · CA · contact PI

CORE--CAREER DEVELOPMENT PROGRAM$83,411

P50 · FY2007 · CA · contact PI

CORE--DEVELOPMENTAL RESEARCH PROGRAM$83,411

P50 · FY2007 · CA · contact PI

NEUROONCOLOGY$25,047

P30 · FY2007 · CA · contact PI

SPORE in Brain Cancer$2,562,260

P50 · FY2006 · CA · contact PI

SRC on Primary and Metastatic Tumors of the CNS$1,347,498

P50 · FY2006 · NS · contact PI

Brain Tumors - Immunological and Biological Studies$645,238

R37 · FY2006 · CA · contact PI

SPORE in Brain Cancer$146,300

P50 · FY2006 · CA · contact PI

CORE--CAREER DEVELOPMENT PROGRAM$49,926

P50 · FY2006 · CA · contact PI

CORE--DEVELOPMENTAL RESEARCH PROGRAM$49,926

P50 · FY2006 · CA · contact PI

NEUROONCOLOGY$24,872

P30 · FY2006 · CA · contact PI

SPORE in Brain Cancer$2,272,282

P50 · FY2005 · CA

SRC on Primary and Metastatic Tumors of the CNS$1,347,498

P50 · FY2005 · NS

Brain Tumors - Immunological and Biological Studies$644,338

R37 · FY2005 · CA

SPORE in Brain Cancer$144,717

P50 · FY2005 · CA

CORE--DEVELOPMENTAL RESEARCH PROGRAM$49,927

P50 · FY2005 · CA

CORE--CAREER DEVELOPMENT PROGRAM$49,927

P50 · FY2005 · CA

NEUROONCOLOGY$24,606

P30 · FY2005 · CA

SPORE in Brain Cancer$2,299,999

P50 · FY2004 · CA

SRC on Primary and Metastatic Tumors of the CNS$1,347,498

P50 · FY2004 · NS

Brain Tumors - Immunological and Biological Studies$628,277

R37 · FY2004 · CA

ADMINISTRATION SUPPORT CORE 5$80,689

P50 · FY2004 · CA

CORE--CAREER DEVELOPMENT PROGRAM$49,977

P50 · FY2004 · CA

CORE--DEVELOPMENTAL RESEARCH PROGRAM$49,977

P50 · FY2004 · CA

SRC ON PRIMARY AND METASTATIC TUMORS OF THE CNS$1,095,066

P50 · FY2003 · NS

Brain Tumors - Immunological and Biological Studies$609,977

R37 · FY2003 · CA

SPORE in Brain Cancer$499,999

P20 · FY2003 · CA

COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$5,608,768

P30 · FY2002 · CA

SRC ON PRIMARY AND METASTATIC TUMORS OF THE CNS$1,091,364

P50 · FY2002 · NS

BRAIN TUMORS - IMMUNOLOGICAL AND BIOLOGICAL STUDIES$524,623

R37 · FY2002 · CA

SPORE in Brain Cancer$499,999

P20 · FY2002 · CA

CORE--GENERAL LABORATORY AND ANIMAL SUPPORT$313,976

P50 · FY2002 · NS

CLINICAL TRIALS WITH SOLID INTRACRANIAL TUMORS &NEOPLASTIC MENINGITIS$313,976

P50 · FY2002 · NS

CORE--IMMUNOINCOMPETENT RODENT &BIOHAZARD FACILITY$187,450

P30 · FY2002 · CA

RAPID DEVELOPMENT OF GLIOMA TARGETING REAGENTS FOR THERAPY$0

P20 · FY2002 · CA

SRC ON PRIMARY AND METASTATIC TUMORS OF THE CNS$1,087,771

P50 · FY2001 · NS

BRAIN TUMORS - IMMUNOLOGICAL AND BIOLOGICAL STUDIES$509,343

R37 · FY2001 · CA

CLINICAL TRIALS WITH SOLID INTRACRANIAL TUMORS &NEOPLASTIC MENINGITIS$313,976

P50 · FY2001 · NS

CORE--GENERAL LABORATORY AND ANIMAL SUPPORT$313,976

P50 · FY2001 · NS

CORE--GENERAL LABORATORY AND ANIMAL SUPPORT$288,255

P50 · FY2001 · NS

CLINICAL TRIALS WITH SOLID INTRACRANIAL TUMORS &NEOPLASTIC MENINGITIS$288,255

P50 · FY2001 · NS

CORE--IMMUNOINCOMPETENT RODENT &BIOHAZARD FACILITY$187,450

P30 · FY2001 · CA

CORE--IMMUNOINCOMPETENT RODENT &BIOHAZARD FACILITY$187,450

P30 · FY2001 · CA

CORE--IMMUNOINCOMPETENT RODENT &BIOHAZARD FACILITY$187,450

P30 · FY2001 · CA

SRC ON PRIMARY AND METASTATIC TUMORS OF THE CNS$16,601

P50 · FY2001 · NS

CORE--IMMUNOINCOMPETENT RODENT &BIOHAZARD FACILITY$0

P30 · FY2001 · CA

SRC ON PRIMARY AND METASTATIC TUMORS OF THE CNS$1,063,812

P50 · FY2000 · NS

BRAIN TUMORS--IMMUNOLOGICAL AND BIOLOGICAL STUDIES$454,245

R37 · FY2000 · CA

CORE--GENERAL LABORATORY AND ANIMAL SUPPORT$288,255

P50 · FY2000 · NS

CLINICAL TRIALS WITH SOLID INTRACRANIAL TUMORS &NEOPLASTIC MENINGITIS$288,255

P50 · FY2000 · NS

CORE--GENERAL LABORATORY AND ANIMAL SUPPORT$188,805

P50 · FY2000 · NS

CLINICAL TRIALS WITH SOLID INTRACRANIAL TUMORS &NEOPLASTIC MENINGITIS$188,805

P50 · FY2000 · NS

SRC ON PRIMARY AND METASTATIC TUMORS OF THE CNS$75,000

P50 · FY2000 · NS

CORE--IMMUNOINCOMPETENT RODENT &BIOHAZARD FACILITY$0

P30 · FY2000 · CA

CORE--IMMUNOINCOMPETENT RODENT &BIOHAZARD FACILITY$0

P30 · FY2000 · CA